{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper bound of 95% confidence interval (CI) were not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"12.12","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"DFS was defined as the time from the date of first dose of study treatment to the time of one of the following events, whichever occurred first: (1) The first recurrence of high-risk disease (high-grade Ta, any T1 or CIS), (2) progression to muscle invasive bladder cancer (MIBC) (T greater than or equal to \\[\\>=\\] 2) or to lymph node (N+) or to distant disease (M+), whichever occurred first, (3) Death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with papillary disease only, received TAR-200 intravesically Q3W from Week 0 for the first 24 weeks, followed by Q12W dosing through Week 99. TAR-200 was inserted intravesically via UPC.","id":"OG000","title":"Cohort 4: TAR-200 Monotherapy (Papillary Disease Only)"}],"paramType":"MEDIAN","populationDescription":"FAS included all enrolled participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"From date of first dose up to clinical cut-off date 3rd July 2025 (up to 50 months)","title":"Cohort 4: Disease-free Survival (DFS)","type":"PRIMARY","unitOfMeasure":"months"}